Product Images Duloxetine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Duloxetine NDC 55154-2579 by Cardinal Health 107, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Bag Label - 72CF23B2 0F13 480C 9AF7 D8F19EE29A8D 00
AHP74501
Figure 1: Cumulative Proportion of Adult Patients with MDD Relapse (Study MDD-5) - Figure1
This text appears to be a graph illustrating the proportion of patients with relapse over time. The graph shows the treatment options of placebo and duloxetine. The x-axis represents the time from randomization to relapse in days, while the y-axis represents the proportion of patients with relapse. The graph is divided into intervals of 0.2, ranging from 0 to 1. The graph suggests that the proportion of patients with relapse decreases over time for both the placebo and duloxetine treatments.*
Figure 10: Percentage of Adult Patients with OA Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity (Study OA-1) - Figure10
Figure 2: Cumulative Proportion of Adult Patients with GAD Relapse (Study GAD-4) - Figure2
This text appears to be a graph showing the proportion of patients with relapse over time, categorized by treatment (placebo or duloxetine). The x-axis represents the time from randomization to relapse in days, ranging from 0 to 300. The y-axis represents the proportion of patients, ranging from 0.0 to 1.0. The graph shows data points at 0.0, 0.2, 0.4, 0.6, 0.8, and 1.0 on the y-axis, and 0, 50, 100, 150, 200, 250, and 300 on the x-axis.*
Figure 3: Percentage of DPNP Adult Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity (Study DPNP-1) - Figure3
Figure 4: Percentage of DPNP Adult Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity (Study DPNP-2) - Figure4
Figure 5: Percentage of Adult Fibromyalgia Patients Achieving Various Levels of Pain Relief at Study Endpoint as Measured by 24-Hour Average Pain Severity (Study FM-1) - Figure5
Figure 6: Percentage of Adult Fibromyalgia Patients Achieving Various Levels of Pain Relief at Study Endpoint as Measured by 24-Hour Average Pain Severity (Study FM-2) - Figure6
This text appears to be a chart or graph showing the percentage of patients who experienced improvement in pain levels when taking different doses of a medication called Duloxetine. The chart shows three different doses: 120 mg once daily, 60 mg once daily, and 20 mg once daily. The x-axis represents the percentage improvement in pain from baseline, while the y-axis represents the number of patients. The chart also includes a line for the placebo group. The chart ranges from 0% improvement to 100% improvement.*
Figure 8: Percentage of Adult Patients with CLBP Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity (Study CLBP-1) - Figure8
Figure 9: Percentage of Adult Patients with CLBP Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity (Study CLBP-3) - Figure9
Percentage of Patients Improved: - The text indicates that there is a percentage of patients who have shown improvement. - The specific percentage is not available or readable. Considering the lack of specific information, the details regarding the improvement, such as the type of patients, the nature of the improvement, or any other relevant data, are not available.*
Structural Formula - Structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.